Patient Advocate since 1977

1 Comment

Congressional Cannabis Caucus’ new law for Medical Marijuana patients introduced by California Congressman Rohrabacher

The Respect State Marijuana Laws Act of 2017 Has Been Introduced
By Julia Granowicz on Feb 11, 2017 07:18 am

About a week ago, a handful of lawmakers who call themselves the “Congressional Cannabis Caucus” announced that they intend to introduce legislation that would help protect the cannabis industry from a Department of Justice run by Attorney General Jeff Sessions. Their announcement was just prior to his confirmation – but they believe that his being Attorney General could actually help push some lawmakers into feeling the same urgency to pass such legislation.

As promised, one of those congressmen  – Dana Rohrabacher of California  – has introduced the Respect State Marijuana Laws Act of 2017. This bill was previously introduced twice before, in 2013 and 2015, and didn’t gain enough support either time to make it very far. This time, however, with the uncertainty surrounding how the federal government is going to move forward in handling the cannabis industry – the bill may find more support.

“This is common sense legislation that is long overdue,” said Robert Capecchi, director of federal policies for the Marijuana Policy Project. “It is time to end marijuana prohibition at the federal level and give states the authority to determine their own policies.

There is hope that more legislators will be more inclined to protect an industry that improves lives for patients in medical marijuana states and has entirely ended prohibition in others. Both types of industries have created countless jobs and brought in millions in tax revenue that would have gone straight into the black market otherwise. If the government isn’t ready to change their minds on prohibition, they should at least protect the states’ rights to enact their own laws.

“States throughout the country are effectively regulating and controlling marijuana for medical or broader adult use,” Capecchi said. “Federal tax dollars should not be wasted on arresting and prosecuting people who are following their state and local laws.”

Basically, the Respect State Marijuana Laws Act would prevent the Department of Justice from pursuing cannabis-related cases in states where marijuana is legal, as long as people are operating within the laws in their respective state. With everything that’s going on, many of us are hoping that this piece of legislation will gain the support it needs to be passed – and that, if it does pass, Trump would be ready and willing to sign it into law.

If that were to happen, states could continue to operate as they have – and others would be able to consider legalization with less worries since there will be something binding in place that says the federal government will keep their opinions to themselves and let the states make their own decisions when it comes to cannabis.

Leave a comment

Republican Congressman Introduces Bill That Would Resolve the Conflict Between State and Federal Marijuana Laws, Allow States to Determine Their Own Policies – CBE

Rep. Dana Rohrabacher’s Respect State Marijuana Laws Act exempts marijuana consumers and businesses from federal criminal penalties if they are acting in compliance with state marijuana laws

By Robert Capecchi

WASHINGTON — Republican Congressman Dana Rohrabacher of California introduced legislation in the U.S. House of Representatives on Tuesday that would resolve the conflict between state and federal marijuana laws and allow states to determine their own marijuana policies.

The Respect State Marijuana Laws Act exempts individuals and entities from certain provisions of the Controlled Substances Act if they are acting in compliance with state marijuana laws. This is the third time Rohrabacher has introduced the bill. Twenty of his colleagues in the House, including seven Republicans, co-sponsored the Respect State Marijuana Laws Act of 2015, which was introduced in the 114th Congress.

“This is commonsense legislation that is long overdue,” said Robert Capecchi, director of federal policies for the Marijuana Policy Project. “It is time to end marijuana prohibition at the federal level and give states the authority to determine their own policies.

“States throughout the country are effectively regulating and controlling marijuana for medical or broader adult use,” Capecchi said. “Federal tax dollars should not be wasted on arresting and prosecuting people who are following their state and local laws.”

Eight states and D.C. have enacted laws making possession and cultivation of limited amounts of marijuana legal for adults 21 years of age and older. Four states — Alaska, Colorado, Oregon, and Washington — have established systems for regulating the production and sale of marijuana for adult use. Four additional states that adopted such laws in November — California, Maine, Massachusetts, and Nevada — are in the process of setting up similar systems. Twenty-eight states, D.C., and the U.S. territories of Guam and Puerto Rico have adopted comprehensive medical marijuana laws that allow seriously ill patients to access medical marijuana if their doctors recommend it. Eighteen additional states have adopted limited and/or unworkable medical marijuana laws.

“Nine out of 10 Americans now live in states that have rejected federal marijuana prohibition by adopting some sort of marijuana policy reform,” Capecchi said. “This legislation would ease the tension between state and federal laws to ensure these state-level reforms are successful. It would also help states address the public health and safety priorities shared by state and federal authorities.”

A national Gallup poll released in October shows public support for making marijuana legal in the U.S. has reached a record high of 60%, up from 58% in 2015 and 50% in 2011. The Pew Research Center also released a national poll in October showing support at 57%, up from 53% in 2015. In August 2015, the National Conference of State Legislatures (NCSL) approved a resolution urging the federal government to allow states to determine their own marijuana policies.

“The call for federal marijuana policy reform is growing louder and louder,” said Don Murphy, MPP director of conservative outreach. “Congress needs to listen to their constituents and to state lawmakers, most of whom agree marijuana policy is an issue best left to the states. This is a bipartisan solution that ought to find support on both sides of the aisle.”

Leave a comment

Did the DEA Just Outlaw Hemp-Derived CBD?

A new rule published by the DEA today led many in the cannabis industry to assume the worst – that the agency had decided to crack down on hemp-derived CBD.

Take a deep breath. This is likely not the case.

What the rule actually does is create a new Administration Controlled Substances Code Number for cannabis extracts – concentrates such as shatter, wax or rosin. This is an administrative measure, not an enforcement action; and while an initial reading of the publication might make it seem like an attack on hemp-derived CBD, the rule mentions neither “hemp” nor “CBD” in either the proposed or final rule.

Eric Steenstra, executive director of the Hemp Industries Association, indicated that although his legal team is reviewing the document, “this isn’t how [the DEA] goes about scheduling a substance.”

“If you look at it, it’s all about marijuana extracts and my take on it is that they probably have come across a lot more extracts over the last few years…and they keep track of this stuff,” he explained in an interview with Ganjapreneur. “This is a tracking thing.”

The DEA has codes for everything on the schedule list and, until this rule, the agency was classifying all cannabis products – flower, concentrates, edibles – under one code. The new rule provides a new code – 7350 – for the classification of cannabis extracts.

Steenstra says that a lot of the “hubbub” over this rule is due to the DEA’s response to a question about whether the code applies to CBD. That answer just repeats the opinion of the DEA that CBD derived from a plant containing more than 0.3 percent THC is a controlled substance. However, Steenstra says that most of the hemp grown in the U.S. is produced under Section 7606 of the Farm Bill, which explicitly draws a distinction between marijuana and hemp.

“I don’t think this is a huge change in the law or anything like that,” he said. “I’m not so sure it’s as big a deal as it’s been made out to be.”

Joy Beckerman, an activist and civil litigation paralegal, says that the DEA considers all CBD products, regardless of the THC content of its source, Schedule 1 substances and points to DEA Form 225 as evidence. On page three of that registration form cannabidiol is listed – a change made in April, 2012, long before the either the rule proposal or finalization.

“The DEA has always – has never not – considered cannabidiol to be a Schedule One drug,” she explained. “This is not shocking, I knew this was coming. Now that the DEA has finalized this July 5, 2011 proposed rule, we have lost an available argument, whereas we’ve been able to say until December 7, 2016 that the rule had never been adopted or finalized. ”

According to the “Regulatory Flexibility Act” section of the publication, in which the DEA would have to explain the economic impacts of the new rule, the agency determines that “it will not have a significant economic impact on a substantial number of small entities.” If the rule were to, in some way, outlaw hemp-derived CBD production, the business entities impacted would need to be divulged in this section – and there would clearly be an economic impact in every state with medical cannabis laws, not to mention for every industrial hemp producer in the U.S.

Basically, CBD oil derived from plants that contain higher than 0.3 percent not grown under Section 7606 will be tracked and classified by the DEA using the same code as concentrates that are high in THC. Researchers who are studying, or planning to study, CBD will have to use this new code if their product is derived from a plant that contains more THC than allowed under the Farm Bill.

According to Alli Cloyd, assistant director of the National Hemp Association, the organization is doing its diligence by looking over the publication with counsel, but said in an email that they aren’t “too worried…considering the federal definition of marijuana makes CBD legal.”

Cloyd said the NHA has been in contact with counsel from Kentucky Sen. Mitch McConnell’s office – a powerful ally to the hemp industry – who indicated that the Republican would “be calling the DEA this week to get their official opinion on its impact.”

In 2001, the DEA clarified its rules, explicitly permitting the use of hemp-derived products that do not cause THC to enter the body. The FDA considers CBD derived from industrial hemp to be a dietary supplement.

Beckerman says the CBD industry should consider suing the DEA over the rule “to really hold their feet to the fire,” saying that the only reason the DEA hasn’t come after CBD companies is because “it would cost them a bazillion dollars in legal arguments.”

“It’s defensible. Is it legal? Of course not,” she argues. “There are so many layers to the legal arguments that they don’t want to get involved in them.”

Leave a comment

European Parliament Hosts International Conference on Medical Cannabis

European Parliament Hosts International Conference on Medical Cannabis
By Bill Griffin on Dec 07, 2016 09:28 am

On November 24th, the European Parliament in Brussels hosted its first international conference on medical cannabis. Cannabis experts, doctors, patients and representatives of the cannabis industry in Europe gathered to attend the three hour event.

It was an icy cold day and my car informed me that it was -4 degrees Celsius as I made my way into Brussels. Thankfully, the sun was shining. Colleagues (as we all work for the plant) and friends that I have been picking up along the way from the cannabis industry were converging in “the belly of the beast” to have a sensible conversation as to how medical cannabis is going to work in Europe.

European Parliament hosts International Conference on Medical Cannabis. Image Credit: Bill Griffin

Responsibility to provide safe access

Saul Kaye, CEO of iCan, couldn’t have summed the situation up better: “It’s not a matter of if, but when and how you make safe medical cannabis available in Europe. The industry is coming and it will make a lot of money. Not giving patients access to cannabis is negligence on behalf of regulators and they have a responsibility to provide this safe access, not to block it.”

Opening the conference, MEP Stelios Kouloglou spoke of how cannabis leads to economic growth. “Cannabis is the fastest growing sector of the US and Israeli economies. The EU has been left behind.” With regards to health he said, “We want to save lives, we know cannabis can help with many serious diseases. We shouldn’t act like we are in the dark ages and be guided by outdated laws from last century but must be guided by science.”

Introducing the first of two panels, Graham De Barra of Help not Harm, an organization supporting a realistic, evidence-based approach to drug policy in Ireland, reminded us that “we must integrate people into health services and away from the harmful black market”.

Doctors in the house

Well represented on the panels of the day were practitioners who had positive results with medical cannabis for their patients. Dr. Dominique Lossignol, who is a specialist in cancer and pain treatment, prescribes medical cannabis to patients in Belgium. He explained that the human body produces a huge amount of cannabinoids and that “there is a gap in our current medicine, and that gap is cannabinoids. We need them for the best treatment of pain.”

Dr. Franjo Grotenhemen (on hospital bed) addresses the conference. Panel two (from left): Petros Evokes, Manuel Guzman, MEP Katerina Konecna, Carola Perez, Saul Kaye. Image Credit: Bill Griffin

Dr. Franjo Grotenhemen, President of the International Association for Cannabinoids as Medicine and Chairman of the Medical Cannabis Declarationin Germany spoke of our “fundamental human right to good health.” Dr. Grotenhemen, who was speaking from a hospital stretcher for reasons that were not mentioned, said, “Patients have the right and the ability to treat themselves and we don’t allow it.”

He concluded with a powerful statement that makes things so clear, “Patients should have the right to access cannabis and doctors should have the right to prescribe it.”

Scientific evidence

“The next revolution in medical cannabis is science,” explained Pavel Kubu, Director of the International Cannabis and Cannabinoids Institute. He described the work of ICCI in “unlocking the database of nature” through the utilisation of big data and tools and the work of ICCI in providing Patient Focused Certification across Europe.

Globally we have made so many gains in recent years under extremely restrictive conditions, yet we are not even scratching the surface of the benefits that this amazing plant can offer. Imagine how things will change when we allow our great institutes of science to explore cannabis further as they see fit.

Patient patience is running out

Listening to politicians, doctors and scientists is great, but you have to remember it is patients from all ages and walks of life who are suffering due to the dis-harmonisation of laws and regulations across Europe when it comes to medical cannabis and cannabis research.

Panel one (from left): Pavel Kubu, Majda Robić, Giorgos Oikonomopoulos, Graham De Barra, MEP Stelios Kouloglox, Alessandro Piccioli, Dimos Fotopoulos, Dominique Lossignol, Bertrand Rambaud. Image Credit: Bill Griffin

Patient testimonials snap us right back into the reality and the urgency of the situation we are in. People are literally dying because they cannot get access to cannabis through their health systems.

One panellist spoke of patients dying with their medical cannabis prescription in hand without ever obtaining their medicine. This is the cruel consequence of global law’s inability to catch up with knowledge that is spreading around the world at the speed of a mouse click; doubly so as the laws were put into place under suspect circumstances.

CBD for Ava

We heard from several patients and caregivers on how cannabis has helped their situation. By far the most moving account was from a brave mother of four, Vera Twomey from Barry in Ireland. Vera’s little girl Ava suffers from dravet syndrome – which is a severe form of epilepsy that affects an estimated 1 in every 20,000–40,000 births. There was not a dry eye in the forum as Vera described how she was told that her baby would never talk or walk. Vera described how specialists had laughed at her when she dared to suggest her child would walk.

She recalled how seven seizures every two hours would cripple the body of poor Ava. As soon as she was able to get her daughter CBD oil the seizures had reduced to only seven in one entire month. That’s a whopping 92% decrease. She’s now attending school and walking, talking and even dancing. I tell you, put lovely Vera in the room with all those standing in the way of legal, medical cannabis-derived products getting to the patients that need them, and things will soon be resolved.

At the time of this writing, Vera’s petition to the Irish Minister of Health is just shy of the 25,000 signatures it needs. If you have a heart, please sign.

Homegrown is not medicine

I learned that there is and needs to be a distinction between homegrown and medical cannabis. Medicine is not easy to bring to market and there are many mechanisms to ensure safety. The level of cleanliness and documentation that goes into creating the medicine you get from your pharmacy goes beyond what many can possibly imagine.

Though often jeered at from the cannabis community, Bedrocan actually offers dried cannabis flower that adheres to the necessary requirements needed to get a “drug” distributed through existing pharmacies. Even in Germany – where strict adherence to regulations is an art form. That is a major achievement for the Dutch company.

Decriminalising the ability for someone to grow their own plant is not providing them medicine. You can produce aspirin from the bark of a willow tree, but how would you react if your doctor gave you a prescription telling you to do just that?

Human rights are being seriously abused here and we urgently need to collectively work towards a system that gives people safe access to cannabis.

Closing the conference, MEP Stefan Eck spoke of how a topic that had once been so taboo is now provoking so much conversation. He said, “Cannabis has been used for centuries and it is time to legalise now for use in Europe.”

The amount of panelists and speakers within such a short timeframe was intense, to say the least. It was like a three day medical and scientific conference had sex with a speed dating event and gave birth to this conference in the EU Parliament, which transpired over a few short hours. Though a little manic in speed the end result left me feeling very optimistic on cannabis being – at the very least – available to those who need it most in as safe a manner as possible.

Leave a comment

CBD oil reduces the frequency and severity of seizures in children and adults with severe, intractable epilepsy, according to findings presented by researchers from the University of Alabama at Birmingham at the American Epilepsy Society 70th Annual Meeting.

BIRMINGHAM, Ala. Dec. 3, 2016 – Cannabidiol oil, also known as CBD oil, reduces the frequency and severity of seizures in children and adults with severe, intractable epilepsy, according to findings presented by researchers from the University of Alabama at Birmingham at the American Epilepsy Society 70th Annual Meeting.

UAB researchers presented eleven abstracts, or research findings, at the meeting. A key finding was that CBD provided a significant reduction in frequency of seizures for a majority of the patients in the study, and that approximately two-thirds of patients saw a greater than 50 percent reduction in severity.

“It is encouraging that both frequency and severity of seizures appear to improve in the majority of patients in our study, patients who have limited treatment options,” said Jerzy P. Szaflarski, M.D., Ph.D., professor in the Department of Neurology and director of the UAB Epilepsy Center. “Our research adds to the evidence that CBD may reduce frequency of seizures, but we also found that it appears to decrease the severity of seizures, which is a new finding.”

The results were based on an open-label study of 81 patients — 42 children and 39 adults — who experienced four or more seizures per month. UAB launched the studies of CBD oil as a treatment for severe, intractable seizures in April 2015. The studies, an adult study at UAB and a pediatric study at Children’s of Alabama, were authorized by the Alabama Legislature in 2014 by legislation known as Carly’s Law.

After one month of beginning CBD therapy, 68 percent of the patients had experienced a greater than 25 percent reduction in seizure frequency; 58 percent had a greater than 50 percent reduction; 36 percent had a greater than 75 percent reduction and 9 percent were seizure-free. Those results were maintained at three and six months.

To assess seizure severity, researchers led by Jenifer DeWolfe, M.D., associate professor of neurology, used the Chalfont Seizure Severity Scale, a questionnaire given prior to therapy and re-administered at intervals throughout treatment. Fifty-seven patients were followed for three months: 67 percent experienced a more than 50 percent decrease in seizure severity, while 33 percent did not. Of 47 patients followed for six months, 64 percent had a greater than 50 percent decrease in seizure severity and 36 percent did not.

“These are encouraging results, but it is important to note that each patient may respond differently to CBD, and the dose for optimal seizures control varies,” said Martina Bebin, M.D., professor of neurology and co-primary investigator of the CBD studies. “There appears to be an optimal CBD dose range where the patient achieves maximum benefit. If outside this CBD dosing range, the seizure frequency may not improve and may even increase. More research is needed, including determining why and how CBD helps some people with epilepsy but not others.”

Among the other UAB abstracts presented at the AES meetings:

• CBD oil was associated with an improvement in mood, an effect independent of the extent of seizure reduction. Lead author Pongkiat Kankirawatana, M.D., professor of pediatrics, says CBD oil may have overall positive effects on mood, which should be further investigated in patients with epilepsy and other chronic conditions in controlled studies.
• A study led by Szaflarski and Bebin found that the optimum dose in both children and adults was between 20 and 25 mg/kg/day.
• Jane Allendorfer, M.D., assistant professor of neurology, found that CBD, in a selected group of patients with epilepsy who experienced overall improved seizure control, has the potential for positive cognitive effects that are associated with corresponding fMRI signal changes.
• One abstract reports on an interaction between warfarin, a drug used as an anticoagulant, and CBD. This underscores the importance of monitoring appropriate laboratory work in patients receiving CBD oil along with other medications, according to study lead Brannon Vines, M.D., a clinical neurophysiology fellow.
• Significant drug interactions were identified between CBD and commonly-used medications for epilepsy, including clobazam, rufinamide, topiramiate, zonisamide and eslicarbazepine. This study, led by neurology fellow Tyler Gaston, M.D., emphasizes the importance of monitoring anti-epilepsy drug levels during treatment with CBD.
• Electrical discharges measured by EEG decreased significantly after initiation and maintenance of CBD, particularly in pediatric patients, according to a study led by Leslie Grayson, M.D., a neurology fellow.
• Using fMRI imaging, Amber Gregory, a graduate student in psychology, showed that persons with epilepsy showed gains in working memory that were associated with a shift in neural recruitment as examined with functional MRI.
• An abstract aimed at examining associations between social determinants of health, such as age, gender and socioeconomic factors against health status, quality of life and mood states showed that higher age and low income were associated with lower health ratings among epilepsy patients, according to study led Magdalena Szaflarski, Ph.D., assistant professor of sociology.

The studies are designed to test the safety and tolerability of CBD oil in patients with intractable seizures. CBD oil, a derivative of the cannabis plant, is delivered orally as an oily liquid.

The oil used in the studies is produced under stringent requirements of the United States Food and Drug Administration by a licensed pharmaceutical company. It contains only traces of THC, the psychoactive component of marijuana. The process developed by GW Pharmaceuticals guarantees the consistency of the product that is provided to study participants.


Leave a comment

Isodiol Launches New Division – Isodiol Medical at A4M World Congress of Anti-Aging in Las Vegas, NV December 9-11, 2016

CARLSBAD, CA / ACCESSWIRE / December 8, 2016 / Isodiol, the Southern California-based cannabinoid innovator, is proud to announce its new division: Isodiol Medical. The Isodiol Medical product line was created out of the passion for expanding education about and improving access to the finest pharmaceutical-grade cannabinoid infused products for pain management and neurological disorders.

Plant derived cannabinoids communicate with every organ and system in the body via the endocannabinoid system to help restore and maintain homeostasis, both physically and mentally. The cannabinoids used in all Isodiol products are derived from hemp, not marijuana. There are more than 100 known active cannabinoids that account as much as 40 percent of the extract that can be taken from industrial hemp.

While both hemp and marijuana are classified as cannabis; the two plants are distinctly different. Marijuana contains the cannabinoid tetrahydrocannabinol (THC) which is the psychotropic component that results a person getting “high”. Isodiol Medical products are THC Free and the CBD is derived from the hemp plant meeting all legal mandates. Therefore, Isodiol Medical’s products cannot and will not produce a psychotropic effect.

Commitment to Sustainability and Quality

Isodiol Medical products begin with European certified organic hemp that is cultivated to the highest standards and there has been no sacrifice to the ongoing commitment to sustainable agriculture. Isodiol Medical sources its hemp from non-GMO crops grown without pesticides, herbicides, or insecticides; laboratory tests and resulting certificates of analysis (COA) are generated for each imported shipment. In addition, all Isodiol CBD is processed under ISO 9001 certification. This certification holds the Company, its processes, and its products to the highest of standards of quality.

The Science Backing Isodiol Medical

Dr. David Tonkin

As a board certified physician specializing in pain management and anesthesia, Dr. David Tonkin has years of experience with effective pain management solutions. After completing a fellowship in Interventional Pain Management, Dr. Tonkin has gone on to become an award-winning author, research scientist, renowned pain therapy expert and teaches physicians throughout the country in pain management techniques and procedures. By fostering key relationships worldwide, Dr. Tonkin and his medical science team have worked with Isodiol Medical to bring together experienced chemists, professors, and technicians who have performed 15 years of in­depth study of hemp plants and cannabinoid-infused hemp oil. These studies have resulted in unique cultivars that Isodiol Medical uses in its products and their cutting-edge delivery systems. This expertise combined with Dr. Tonkin’s extensive experience in pain management and treatment has culminated in the creation of the RapidCBD line of products.

Dr. Ronald Aung-Din

A board-certified neurologist by the American Board of Psychiatry and Neurology with over 35 years of experience, Dr. Ronald Aung-Din is a member of the American Academy of Neurology and a proud recipient of the Patients’ Choice Award. Specializing in epilepsy, multiple sclerosis, Alzheimer’s disease and dementia, migraine and tension headaches and other disorders and diseases, he has seen a plethora of conditions for which the benefits of cannabinoids have been shown effective. Dr. Aung-Din is also active in treating varied neurological and psychiatric conditions using delivery of CNS-active drugs with Direct Effects topical delivery, a technology developed by him for which 7 patents have to date been granted in the United States, Europe, and Australia; with others pending. Dr. Aung-Din developed IsoDerm™ to help bring relief to an array of maladies. This patented formula is placed on the back of the neck and effectively works to alleviate pain and reduce or even stop seizures.

Isodiol Medical Products:

The products in the Isodiol Medical line are designed to provide natural forms of benefits and overall balance through a variety of delivery systems. From topical to oral formulations, each product is created with the most scientifically advanced, bio-available forms of cannabinoids on the market. Isodiol’s proprietary CBD99 Crystalline incorporated in each Isodiol Medical product is 99+% pure.

With typical cannabinoid-infused products, 90% or more is wasted because cannabinoid particles measure about 2,000 nanometers. Human cells can only absorb particles of 60-80 nanometers. Nano-Amplified cannabinoid-infused products from Isodiol are 100% bioavailable because nano-emulsification reduces the molecules down to 16 nanometers, as evidenced in recent lab results. With nano-amplified cannabinoids, the body can immediately optimize use all of the molecules.

Topical Solutions:

Topical Isodiol Medical formulas are powerful due to the nano-amplified cannabinoids in Cebidiol™ that are microencapsulated into layers. The tiny ingredients are suspended and released at intervals, providing consistent relief that lasts. Encapsulation makes permeation through the skin more effective. These easily absorbable formulations eliminate any possible irritation and optimize each application. Delivery is more effective due to the powerful concentration and duration on the dermis and epidermis. And the encapsulated material won’t metabolically degrade because it is protected by the liposomal encapsulation.

RapidCBD™ Pain Cream – Delivering an instant and continual cooling, soothing, pain relief experience, RapidCBD™ combines micro-encapsulated, time-released Cebidiol™ with stimulating menthol and 8 homeopathic ingredients, along with lavender and rosemary essential oils to relieve aches and pains. This gel cream is ideal for use after strenuous activity and has been proven to be effective and work fast as an FDA approved OTC topical pain relief solution.

RapidCBD™ Patch – The convenient and discrete RapidCBD™ Pain Patch combines the power of Cebidiol™ with lidocaine and menthol, for the best in both traditional pain relief and the latest in cannabidiol science. The addition of Lidocaine gives the RapidCBD™ Patch soothing anesthetic properties for up to 12 hours a day, when and where your body needs it. It calms nerves, stopping pain impulses to the brain. Menthol adds analgesic qualities, cooling and warming the skin and penetrating deeply to help relieve pain in muscles and tendons. The RapidCBD™ Patch delivers convenient pain relief for muscle aches, back pain, arthritis, and joint pain.

IsoDerm™ – Placed on the back of the neck, IsoDerm™ delivers the cannabinoids directly to the central nervous system with Direct Effect Technology™.

Oral Solutions:

Isodiol Medical’s oral products combine the benefits of cannabinoids with unique herbal blends. The power of these formulations stems from a perfect balance between the potency of the herbs and the ratios of these extracts. This wisdom has been cultivated and passed down within a line of master herbologists resulting in a formula that works synergistically with the body to restore natural balance.

RapidCBD™ Oral Sprays – Available in three different formulations for discomfort, stress, and cognitive aging, RapidCBD™ Oral Sprays are powered by nanotechnology.

RapidCBD™ Tabs – RapidCBD™ Tabs dissolve immediately when placed under the tongue, delivering 25mg of powerful CBD99 Crystalline per quick dissolving tablet. Membranes in the bottom of the mouth are extremely permeable. Our Rapid TabMelt™ proprietary delivery method takes bioavailability to a new level by circumventing the liver path and avoiding pre-systemic elimination in the GI tract.

RapidCBD™ XtendCBD™ Capsules – Designed for delivery of extended pain relief, XtendCBD™ Capsules provide long lasting effects. These capsules are designed to dissolve in the intestinal track, bypassing the stomach acids delivering more enduring results. Each RapidCBD™ Xtend Cap iscombined with 25mg of Isodiol’s CBD99 Crystalline formula and a proprietary blend of East Asian adaptogenic herbs for a fully balanced formula. The Proprietary Herbal Complex consists ofglucosamine HCI and chondrointin for discomfort, turmeric root powder for anti-inflammatory and anti-oxidant effects, and a host of other herbs.

Isodiol is unveiling the Isodiol Medical products at booth # 8027 during the A4M’s 24th Annual World Congress on Anti-Aging, Regenerative and Aesthetic Medicine December 9th – 11th held at the Sands Expo in Las Vegas, NV. For information on the conference, visit

About Isodiol:

Isodiol and its team of collaborators are a group of companies that together, grow & harvest hemp on an industrial scale, and then process it to extract the non-psychoactive cannabinoids to the highest available purity for worldwide distribution. By utilizing one of the world’s largest hemp farms, Isodiol and its partners are the choice for industrial volumes of high-grade, non-psychoactive cannabinoids. Pharmaceutical, nutraceutical and cosmetic companies worldwide have gained market share due to our products. For more information, visit To follow Isodiol online, visit the Company’s website at, Facebook, Instagram, and Twitter.


Isodiol does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). Cannabinoids are a natural element of industrial hemp. Isodiol’s products are not intended to cure, mitigate or diagnose disease states.

Leave a comment

Berlin likely to semi-legalize marijuana –



Author Jefferson Chase


A coalition of political parties in the German capital has agreed to push for partial decriminalization of cannabis. The initial effects will be limited, but marijuana legalization advocates are still pretty stoked.

Null-Gramm-Regel im Görlitzer Park (picture-alliance/dpa/K. Nietfeld)

Almost completely obscured by the US election was the news that as part of their coalition negotiations to govern the city, Berlin’s Social Democrats, the Greens and the Left Party want to partially allow marijuana use.

Various newspapers cited Green politician Benedikt Lux saying that the three parties had agreed to seek a “scientifically monitored pilot project for the controlled distribution of cannabis to adults.”

That doesn’t sound exactly like bong hits of White Widow or Train Wreck Sweet for all, but advocates say the initiative could be a step toward getting marijuana decriminalized. In the past, explains Max Plenert of the German Hemp Association, attempts by city districts to legalize pot have foundered on the Federal Intoxicants Law, which bans cannabis. Plenert thinks that the entire city, which is also one of Germany’s 16 federal states, has far better chances for success.

“The legal code is decided at the federal level, and this is about a local attempt to try to do things differently,” Plenert told DW. “The Intoxicants Law provides for such experiments. You can apply for exceptions, although the Minister of Health also has influence over the final decision. The state of Berlin has far broader possibilities than a city district in terms of setting up a pilot project. We can make a far more powerful appeal for an exception.”

Leave it to Germany to translate the issue of whether people should be allowed to get high into a rather dry question of political procedure. Marijuana advocates argue that they’re just trying to bring the law in line with reality, particularly in Berlin, a city where it’s easy to buy cannabis and small-time dealing is rarely punished.

Deutschland Berlin - Mutmaßliche Drogenhändler im Park (DW/J. Chase)Görlitzer Park is a well-known spot for buying pot in Berlin

‘I sell marijuana – I’m not a drug dealer’

It’s a frosty Saturday morning, but despite the early hour, Görlitzer Park in Berlin’s Kreuzberg district is already full of mostly African men standing around in small groups. Marijuana dealing is such an open secret that it mocks the very word.


Berlin’s new left-wing government set to change city

Berlin’s new government of the SPD, the Left party and the Greens wants to stop deportations and make the city center radically greener. The coalition is being touted as a blueprint for next year’s general election. (07.11.2016)

Germany gives go-ahead to relax rules on medical marijuana

German police find 230 kilograms of marijuana in truck near Passau

Most local residents don’t particularly object to the dealers, and a much ballyhooed “zero tolerance” policy by the authorities from 2015 ended last month with an internal document being leaked to the press, in which the police admitted that “there has still been no significant displacement of the dealer scene.” The newspaper Berliner Zeitung interpreted that statement to mean that the police had “given up” on the park.

What do the dealers think of the pilot project? Do they see it as a threat to their livelihood? Understandably, these men are very wary of talking with the press, but one eventually tells DW that he has not heard of the pilot project and that there is no general sense of worry among the dealers.

Another – Bobby from Cameroon – opens up even further, saying that he would support the decriminalization of marijuana.

“I think it should be legalized,” Bobby told DW, while puffing on a healthy sized joint. “Hey, we’re Rastafarians from Africa. We smoke weed. We don’t think it’s a drug like cocaine. I sell marijuana. I’m not a drug dealer.”

Plenert says that people like Bobby have no reason to fear being put out of their hardly enviable jobs any time soon, even if Berlin is allowed to authorize some sale of marijuana.

“This is a pilot project with limits,” he says. “It’s an attempt to advance the discussion about how things could be different. It won’t have a massive effect on the market for drugs as a whole. But as with other pilot projects concerning drugs, it’s a chance to show politicians and the press that the topic isn’t such a big deal. And that could kick-start larger changes.”

And to see what sort of changes might be possible, cannabis advocates need only look across the Atlantic.

Hanfparade 2014 in Berlin (Getty Images)The legalization movement looks to the US for inspiration

America getting high again

Donald Trump’s election victory overshadowed the news that on November 9 four US states, including California, legalized possession and recreational use of small amounts of marijuana. Cannabis is now fully legal in eight states and is more or less permitted in a few others.

This latest decriminalization movement began in 2012 when referenda passed in Colorado and Washington allowing people to smoke pot. Legalization advocates in Germany think that their country could follow in the same path.

“This creates pressure,” Plenert says. “California, which alone would be one of the largest industrialized nations in the world, has just legalized marijuana. And the US is a good example because it all started with the idea of cannabis as medicine. People saw images from Colorado and realized that the sky wasn’t falling in. Reporting on the topic became increasingly non-partisan, and the pressure (for legalization) rose.”

Germany’s federal states don’t have the right to pass laws that would contravene the Federal Intoxication Law, but Plenert thinks that the example of America together with the experience of the local exceptions allowed under national law will eventually lead to a change in the way marijuana is treated.

“I think we’ve made enough progress in Germany to recognize that the status quo doesn’t really work,” he says. “And to say: If individual federal states want to experiment with something different, let’s give it a try.”

Perhaps Berlin’s pilot project will help those who participate in it overcome the revulsion and anxiety most people in the German capital feel at the other results of America’s Election Day.